R Purcell P - OmicsDI

Show results for

Unknown (313)
Metabolomics (57)
Proteomics (30)
Genomics (10)
Transcriptomics (8)

Organisms

Homo sapiens (36)
Mus musculus (4)
Sarcophilus harrisii (2)
Ovis aries (1)
Sus scrofa (1)
Lama glama (1)
Mustela putorius furo (1)
Pteropus alecto (1)
synthetic construct (code 12) (1)

Repository

MetaboLights (57)
pride (29)
EGA (9)
biostudies-arrayexpress (8)
MassIVE (1)
ENA (1)

Tissue

Cell culture (15)
Lung (4)
B cell (3)
Cell suspension culture (3)
Brain (2)
Peripheral blood mononuclear cell (2)
Permanent cell line cell (2)
T cell (2)
Acute myeloid leukemia cell line (1)
B-lymphoblastoid cell line (1)
Blood (1)
Blood cell (1)
Breast (1)
Diffuse large B-cell lymphoma cell line (1)
Epithelial cell (1)
Fibroblast (1)
HeLa cell (1)
JURKAT cell (1)
Leukocyte (1)
Macrophage (1)
Malignant cell (1)
Melanocyte (1)
Mesothelial cell of pleura (1)

Disease

Breast cancer (2)
Disease free (2)
Brain cancer (1)
COVID-19 (1)
Ewing sarcoma of bone (1)
Fibrolamellar carcinoma (1)
Lung cancer (1)
Malignant pleural mesothelioma (1)
Neuroblastoma (1)
Skin melanoma (1)
Tuberculosis (1)
Type 1 diabetes mellitus (1)

Technology Type

NMR spectroscopy (50)
Mass Spectrometry (29)
Shotgun proteomics (14)
Affinity purification coupled with mass spectrometry proteomics (9)
NMR spectroscopy assay (7)
Immunopeptidomics (3)
Mass spectrometry (2)
Bottom-up proteomics (2)
Data-dependent acquisition (2)
SRM/MRM (2)
SWATH MS (2)
Mass spectrometry assay (1)
Data-independent acquisition (1)
Gel-based experiment (1)
Proteogenomics (1)

Instrument Platform

Nuclear Magnetic Resonance (NMR) - (30)
Bruker (21)
Nuclear Magnetic Resonance (NMR) (7)
NextSeq 2000 (2)
Varian (2)
LTQ Orbitrap (1)
LTQ Orbitrap Elite (1)
TripleTOF 5600 (1)
6490 Triple Quadrupole LC/MS (Agilent) (1)
Liquid Chromatography MS - alternating - reverse phase (1)
Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - hilic (1)
Liquid Chromatography MS - positive - reverse phase (1)
UHPLC system (1290 Agilent) (1)

Publication Date

2021 (17)
2025 (16)
2020 (9)
2018 (9)
2026 (8)
2023 (8)
2015 (6)
2024 (4)
2019 (4)
2017 (4)
2016 (3)
2011 (2)
2022 (2)
2014 (2)
2010 (1)

CHEBI ID

CHEBI:15366 (38)
CHEBI:16737 (36)
CHEBI:15354 (33)
CHEBI:30769 (33)
CHEBI:16919 (32)
CHEBI:30751 (32)
CHEBI:15428 (31)
CHEBI:16977 (29)
CHEBI:15603 (27)
CHEBI:15891 (27)
CHEBI:16414 (27)
CHEBI:18050 (26)
CHEBI:17191 (25)
CHEBI:17295 (25)
CHEBI:17895 (25)
CHEBI:422 (23)
CHEBI:16236 (22)
CHEBI:17268 (22)
CHEBI:16015 (21)
CHEBI:16857 (21)
CHEBI:17750 (21)
CHEBI:15971 (20)
CHEBI:32816 (20)
CHEBI:78320 (20)
CHEBI:15344 (19)
CHEBI:27266 (19)
CHEBI:15741 (18)
CHEBI:20067 (18)
CHEBI:15724 (17)
CHEBI:24898 (17)

Metabolite Name

Choline (29)
Creatinine (29)
Creatine (27)
L-Alanine (27)
L-Valine (27)
L-Isoleucine (26)
L-Phenylalanine (26)
L-Glutamine (25)
L-Leucine (25)
D-Glucose (24)
Glycine (24)
Taurine (23)
L-Tyrosine (22)
L-Histidine (21)
L-Lactic acid (21)
L-Threonine (21)
Acetic acid (20)
Ethanol (20)
Formic acid (19)
L-Glutamic acid (17)
Betaine (16)
Citric acid (16)
Glycerol (15)
L-Proline (15)
Lactate (15)
Myoinositol (15)
Phosphorylcholine (15)
Acetoacetic acid (14)
Acetone (14)
L-Lysine (14)

First Public Date

2020 (1)

Study type

Transcription profiling by array (5)
RNA-seq of coding RNA (2)
Genotyping by array (1)

Release Date

2021 (41)
2022 (30)
2024 (25)
2023 (25)
2018 (20)
2025 (19)
2019 (19)
2016 (17)
2015 (15)
2013 (15)
2011 (14)
2020 (14)
2017 (12)
2014 (12)
2010 (10)
2012 (10)
2026 (8)
2009 (4)
2008 (4)
2007 (3)
2004 (2)
2006 (1)
2002 (1)

Lab affiliation

Deputy Head (Research), Department of Biochemistry and Molecular Biology Head Immunoproteomics Laboratory Infection and Immunity Program Room 214, level 2, 15 Innovation Walk Monash Biomedicine Discovery Institute Monash University, Clayton Campus Clayton 3800 Victoria Australia (3)
Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton 3800, VIC, Australia (2)
ETH Zurich Institute of Molecular Systems Biology (2)
1 Department of Computer Science, Hanyang University, Seoul 04763, Republic of Korea 2 Institute for Artificial Intelligence Research, Hanyang University, Seoul 04763, Republic of Korea (1)
1CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada 2 Department of Pathology and cellular biology, Faculty of Medicine, Universite de Montreal, QC H3T 1J4, Canada (1)
Centre for Proteomic Research B85, Life Sciences Building University of Southampton University Road Highfield Southampton, Hants. SO17 1BJ United Kingdom (1)
Department of Biochemistry and Molecular Biology (1)
Department of Biochemistry and Molecular Biology Head Immunoproteomics Laboratory Infection and Immunity Program Monash Biomedicine Discovery Institute Monash University, Clayton Campus Clayton 3800 Victoria Australia (1)
Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia (1)
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton 3800, Victoria, Australia (lab head) (1)
Department of Biochemistry and Molecular Biology, Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton 3800 Victoria, Australia. (1)
Department of Biochemistry, Monash University, Clayton,3168, Australia (1)
Department of Chemistry and Biomolecular Sciences Macquarie University Sydney, NSW 2109 Australia (1)
Deputy Head (Research), Department of Biochemistry and Molecular Biology Head Immunoproteomics Laboratory Infection and Immunity Program Room 214, level 2, 15 Innovation Walk Monash Biomedicine Discovery Institute Monash University, Clayton Campus Clayton 3800 Victoria Australia (1)
Deputy Head (Research), Department of Biochemistry and Molecular Biology Head Immunoproteomics Laboratory (1)
Deputy Head (Research), Department of Biochemistry and Molecular Biology Head Immunoproteomics Laboratory Infection and Immunity Program Monash Biomedicine Discovery Institute Monash University, Clayton Campus Clayton 3800 Victoria Australia (1)
Deputy Head (Research), Department of Biochemistry and Molecular Biology Head Immunoproteomics Laboratory Infection and Immunity Program Room 214, level 2, 15 Innovation Walk Monash Biomedicine Discovery Institute Monash University Clayton 3800 Victoria Australia (1)
Deputy Head (Research), Department of Biochemistry and Molecular Biology Head Immunoproteomics Laboratory Monash University, Clayton Campus Clayton 3800 Victoria Australia (1)
Deputy Head (Research), Department of Biochemistry and Molecular Biology Head Immunoproteomics Laboratory Monash University, Clayton Campus Clayton 3800 Victoria Australia (lab head) (1)
Deputy Head (Research), Department of Biochemistry and Molecular Biology, Head Immunoproteomics Laboratory, Infection and Immunity Program, Monash Biomedicine Discovery Institute, Monash University, Victoria, Australia (1)
IMSB, ETH Zurich (lab head) (1)
Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia (lab head) (lab head) (1)
Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton 3800, Victoria, Australia (1)
Monash University, Clayton, Australia (1)
Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia (1)

Previous page
1 / 42
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 42
Next page

Sort by:

Relevance

Page size

All-metallic magnetic Purcell enhancement in a thermally stable room-temperature maser.

Not available

S-EPMC12715216 | biostudies-literature

Space-Time Wave Packets from Smith-Purcell Radiation.

Not available

S-EPMC8596120 | biostudies-literature

Purcell-Induced Bright Single Photon Emitters in Hexagonal Boron Nitride.

Not available

S-EPMC11468782 | biostudies-literature

pyRforest: a comprehensive R package for genomic data analysis featuring scikit-learn Random Forests in R.

Not available

S-EPMC11735746 | biostudies-literature

Alagebrium chloride therapy acts to preserve beta cell health

Aims/hypothesis AGEs are considered environmental contributors of type 1 diabetes, but the exact role AGEs play early in pathogenesis of the disease, remains unidentified. We aimed to reduce AGEs with the pharmacotherapy alagebrium chloride in MIN6N8 cells and early in life in NOD mice to determine...

ORGANISM(S): Mus musculus (Mouse)

2021-06-29 | PXD025998 | Pride

Diabetes hla proteomics

IFNγ modulates the immunopeptidome of triple negative breast cancer cells by enhancing and diversifying antigen processing and presentation.

Peptide vaccination remains a viable approach to induce T-cell mediated killing of tumours. To identify potential T-cell targets for Triple-Negative Breast Cancer (TNBC) vaccination, we examined the effect of the pro-inflammatory cytokine interferon-γ (IFNγ) on the transcriptome, proteome and immuno...

ORGANISM(S): Homo sapiens (Human)

2021-05-13 | PXD023044 | Pride

Hla Breast cancer Immunopeptidomics

Immunopeptidomics analysis of mesothelmia cell line

We have analysed a patinet derived mesothelioma cell line by immuniopeptidomics and identified cancer antignes in this line immunopeptidome.

ORGANISM(S): Homo sapiens (Human)

2025-05-06 | PXD037845 | Pride

Immunopeptidomics mesothelmia hla proteomics erv

Untargeted 1 H NMR-based metabolomics unveils distinct circulating biochemical signatures between treatment-resistant and non-treatment-resistant Schizophrenia patients: a pilot study

Schizophrenia is a severe psychiatric disorder impacting roughly 1% of individuals. The effectiveness of antipsychotic therapy greatly varies, with around 30% of patients categorised as treatment-resistant (TRS). TRS is characterised by a lack of response to at least two clinical trials invo...

2025-10-01 | MTBLS12709 | MetaboLights

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining ...

2025-02-27 | MTBLS711 | MetaboLights

R₂ Relaxometry of SABRE-Hyperpolarized Substrates at a Low Magnetic Field.

Not available

S-EPMC10862376 | biostudies-literature

Previous page
1 / 42
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 42
Next page

Sort by:

Relevance

Page size

418 Results

Show results for

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Study type

Release Date

Lab affiliation

OmicsDI is part of the ELIXIR infrastructure

Tweets